US revisits spinal injury coverage decision:
This article was originally published in Clinica
Executive Summary
The Centers for Medicare and Medicaid Services (CMS) has decided to reopen the issue of whether Medicare should cover neuromuscular electrical stimulation for spinal cord injury. The agency decided in 1984 and again in 1991 not to cover the treatment when used to treat the atrophy that occurs as a result of a spinal cord injury. But new clinical evidence has recently appeared, suggesting the treatment may help patients stand and walk. The issue warrants taking another look, CMS said last week.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.